Clinical trials: Schizophrenia Spectrum Disorders
Psychoses, Substance-Induced
Prevention of N-methyl-D-aspartate (NMDA) Antagonist-induced Psychosis in Kids
Ketamine, an FDA approved anesthetic agent, is becoming the sedative/analgesic of choice for emergency sedation in children because it causes deep sedation with minimal respiratory depression in comparison to other available…
- Trial name
- NCT00205712
- Testing
- Ketamine, Dexmedetomidine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Washington University School of Medicine
Schizophrenia, Schizoaffective Disorder
Targeting Physical Health in Schizophrenia: Physical Activity Can Enhance Life Randomized Control Trial
Purpose: To test the effectiveness of an exercise intervention that combines group walking, activity tracking, and heart rate monitoring (i.e.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Brief Psychotic Disorder, Schizophreniform Disorders
- Trial name
- (PACE-life (NCT04173572)
- Testing
- PACE-Life, Exercise Intervention
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of North Carolina, Chapel Hill
Bipolar Disorder, Schizophrenia
Event Marker Ingested To Trigger Event Recorder 3.0 Psychiatry Study
Feasibility study of using a digital health feedback system (DHFS) to monitor medication-taking and physiologic and behavioral parameters in patients with bipolar disorder or schizophrenia.
- Trial name
- EMITTER3PSY (NCT01804257)
- Testing
- Digital Health Feedback System
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Proteus Digital Health, Inc.
Schizophrenia, Schizoaffective Disorder
STimulation to Improve Auditory haLLucinations
Investigating the effects of non-invasive transcranial current stimulation as a treatment for auditory hallucinations in patients with schizophrenia.
- Trial name
- STILL 2 (NCT02360228)
- Testing
- tACS (alpha), tDCS
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of North Carolina, Chapel Hill
Schizophrenia
Intranasal Insulin Treatment in Patients With Schizophrenia
This study is an 8-week, randomized, double-blind, placebo-controlled trial of intranasal insulin as an adjunctive therapy, with a 4-week follow-up, in 60 non-diabetic schizophrenia subjects to examine insulin's effect on…
- Trial name
- NCT00575666
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Massachusetts, Worcester
Alzheimer Disease
Home-based Transcranial Direct Current Stimulation (tDCS) for Behavioral Symptoms in Alzheimer's Disease and Related Dementias (ADRD)
The purpose of this study is to assess acceptability, and safety of providing tDCS to ADRD patients with behavioral symptoms and to assess the efficacy of tDCS for ADRD-related symptoms, mainly behavioral symptoms.
- Trial name
- NCT05478681
- Testing
- active tDCS
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- The University of Texas Health Science Center, Houston
Schizophrenia, Schizoaffective Disorder
Treatment of Negative Symptoms of Schizophrenia With Transcranial Magnetic Stimulation (TMS)
This study will test whether repetitive transcranial magnetic stimulation (rTMS) is helpful in treating negative symptoms and social deficits of schizophrenia.
- Trial name
- NCT00517075
- Testing
- Transcranial Magnetic Stimulation (TMS), repetitive transcranial magnetic stimulation
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- New York State Psychiatric Institute
Schizophrenia
Adjuvant Treatment With a Glycine Uptake Inhibitor in Participants With Negative Symptoms of Schizophrenia (P05695) (MK-8435-001)
The purpose of this study is to determine whether MK-8435 (Org 25935) is more effective than placebo in improving negative symptoms in participants with schizophrenia who are concurrently treated with a stable dose of a second…
- Trial name
- GIANT (NCT00725075)
- Testing
- MK-8435 (Org 25935) 4-8 mg, MK-8435 (Org 25935) 12-16 mg
- Volunteers
- 215 people
- Sponsor
- Merck Sharp & Dohme LLC
Schizophrenia
A Short Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia
The objective of this study is to investigate the efficacy and safety of three different doses of aripiprazole (2 mg/day, 6-12 mg/day, 24-30 mg/day) orally administered over a period of 6 weeks in pediatric patients (aged 13-17…
- Trial name
- NCT01942161
- Testing
- Aripiprazole Low (2 mg/day), Aripiprazole Mid (6 - 12 mg/day), Aripiprazole High (24 - 30 mg/day)
- Where
- 8 sites in Japan
- Volunteers
- 106 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Schizoaffective Disorder, Psychotic Disorder
Evaluation of Effectiveness and Safety of Paliperidone Extended Release in Patients With Schizoaffective Disorder.
The purpose of this study is to measure the effectiveness and assess the safety of two dosages of the antipsychotic paliperidone extended-release (ER) in patients who are experiencing an acute episode of schizoaffective disorder.
- Trial name
- NCT00397033
- Testing
- Paliperidone ER
- Volunteers
- 316 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
A Positron-Emission-Tomography (PET) Study to Measure the Blockade of Dopamine Receptors (D2) in Specific Areas of the Brain in Relation to the Plasma Concentrations of Paliperidone Extended Release (ER) and Oral Risperidone in Schizophrenia Patients and Healthy Controls
The primary objective of this study is to compare the effect of two different antipsychotic compounds which are used in the treatment of schizophrenia (paliperidone ER and risperidone) at their target sites in two specific areas…
- Trial name
- NCT00934635
- Testing
- Paliperidone ER, Oral risperidone, PET Scan
- Where
- Germany
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Janssen-Cilag G.m.b.H
Schizophrenia
Study of Efficacy of PEAR-004 in Schizophrenia
The purpose of the study was to determine in patients currently being administered antipsychotic pharmacotherapy whether PEAR-004 could further reduce symptoms of schizophrenia as measured by the Positive and Negative Syndrome…
- Trial name
- NCT03751280
- Testing
- PEAR-004
- Where
- 6 sites in United States
- Volunteers
- 112 people
- Sponsor
- Novartis Pharmaceuticals
Schizophrenia
A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
A clinical trial to study the efficacy and safety of an investigational drug in acutely psychotic people with schizophrenia. Participants in the study will either receive the drug being studied or a placebo.
- Trial name
- NCT04072354
- Testing
- SEP-363856 50mg, SEP-363856 75mg
- Where
- 53 sites in United States, Bulgaria and 4 more
- Volunteers
- 463 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Multiple Ascending Doses of PF-04958242 in Subjects With Stable Schizophrenia
This study aims to assess the safety, tolerability and pharmacokinetics of PF-04958242 in multiple ascending doses in subjects with stable schizophrenia.
- Trial name
- MAD (NCT02332798)
- Testing
- PF-04958242
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Biogen
Schizophrenia, Cigarette Smoking
Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors
This is a 8-week double-blind placebo controlled parallel group study of the efficacy of varenicline (Chantix) for smoking cessation in schizophrenic patients, and its effect on cognitive function in patients with…
- Trial name
- NCT00802919
- Testing
- Varenicline
- Where
- 4 sites in United States, China and 1 more
- Volunteers
- 93 people
- Sponsor
- Nathan Kline Institute for Psychiatric Research
Psychotic Disorders
Mobile After-Care Intervention to Support Post-Hospital Transition (MACS)
This study examines the feasibility and acceptability of a mobile device-delivered app, called Mobile After-Care Support (MACS), to improve patients' coping and treatment adherence following a hospitalization related to their…
- Trial name
- MACS (NCT03769493)
- Testing
- Mobile After-Care Support (MACS) app
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Butler Hospital
Psychotic Disorders
Transcranial Brain Stimulation and Its Underlying Neural Mechanisms as a Novel Treatment for Auditory Hallucinations
The present study aims to investigate whether transcranial direct current stimulation (tDCS) reduces auditory hallucinations in patients with psychosis. In addition, the neuronal changes of tDCS will be examined.
- Trial name
- NCT02769507
- Testing
- DC Stimulator PLUS (NeuroConn)
- Where
- Norway
- Volunteers
- 24 people
- Sponsor
- University of Bergen
Schizophrenia, Schizoaffective Disorder
Efficacy of an Early Antipsychotic Switch in Case of Poor Initial Response to the Treatment of Schizophrenia
The main aim of the trial is to study whether a change of medication in non-responders to a two-weeks antipsychotic drug trial is more effective than continued treatment with the same antipsychotic.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT01029769
- Testing
- Olanzapine or amisulpride
- Where
- Germany
- Volunteers
- 350 people
- Sponsor
- Technical University of Munich
Schizophreniform Disorder, Schizoaffective Disorder
Open-label Ziprasidone Study for Psychosis Treatment in Adolescents
This open-label study will assess the medication Geodon® (Ziprasidone) in pediatric patients, aged 13-17, diagnosed with psychotic disorder.
- Conditions
- Schizophreniform Disorder, Schizoaffective Disorder, Psychosis, Depressive Disorder, Major
- Trial name
- NCT00421954
- Testing
- Ziprasidone
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- New York State Psychiatric Institute
Schizophrenia
Does Acute Oxytocin Administration Enhance Social Cognition in Individuals With Schizophrenia?
Individuals with schizophrenia have been found to have deficits in social cognition, which is defined as the functions that are engaged during social interactions.
- Trial name
- NCT01312272
- Testing
- Oxytocin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- VA Greater Los Angeles Healthcare System